SIGAHealthcare · Drug Manufacturers - Specialty & Generic

SIGA Stock Forecast: SIGA Technologies, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026

$3.32

+3.59% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 27 Oct 2026 — in the lower half.

Market cap

$229.9M

Ticker Nerd rank

45/ 100

Median analyst target

—

Analysts covering

Revenue$41.0M−49.5% y/y

Operating income$13.9M

Net income$12.5M

Free cash flow$15.2M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+6.3%

−4.2%

YTD

−39.6%

−56.3%

From 52W high

−56.3%

From 52W low

+15.5%

$2.87

$7.58

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

SIGA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SIGA Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026

45/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility

Value

Quality

Issuance

Size

Accruals

Revisions

Growth

Momentum

Volatility (97): The share price has been relatively steady.

Momentum (13): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SIGA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SIGA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
6 Nov 2012	Wedbush	Maintains	Outperform	$11 → $7.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SIGA appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

SIGA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, SIGA Technologies, Inc. returned −56.3% against +13.6% for the S&P 500, dividends included.

SIGA vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SIGA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

EPS revision, 90 days

−66.7%

Analysts raising

Analysts cutting

Fundamentals

SIGA Technologies, Inc. (SIGA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 11.3×
Price / sales: 4.3×
Price / book: 1.4×
EV / EBITDA: −10.7×

Growth & margins

Revenue growth (YoY): −49.5%
Earnings growth (YoY): −64.9%
Gross margin: 57.2%
Operating margin: 33.9%
Net margin: −5.2%

Returns & dividend

Return on equity: −1.5%
Return on assets: −3.4%
Dividend yield: 74.3%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SIGA Technologies, Inc. (SIGA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

SIGA Technologies, Inc. has a market value of $229.9M and an enterprise value of $112.8M.
Revenue in the twelve months to 30 June 2026: $53.7M. The latest quarter shrank 49.5% year on year.
Net income over the same four quarters: −$2.8M, a −5.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$20.5M, after $330K of capital spending.
SIGA Technologies, Inc. spent $43.6M on dividends in the twelve months to 30 June 2026.
Shares outstanding: 71.8M.
Trailing P/E: 11.3×; forward P/E: 3.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 74.30%, paying out 0% of earnings.
SIGA Technologies, Inc. employs 49 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

SIGA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
SIGASIGA Technologies, Inc.	$229.9M	45
BIOABioAge Labs, Inc.	$242.8M	40
LFCRLifecore Biomedical, Inc.	$244.1M	3
ADCTADC Therapeutics SA	$197.0M	81
ANIKAnika Therapeutics, Inc.	$286.1M	99
ACBAurora Cannabis, Inc.	$290.8M	—
AKBAAkebia Therapeutics, Inc.	$176.9M	76

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SIGA Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SIGA news & analysis

SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®

GlobeNewsWire · 28 Oct 2026positive

SIGA Technologies secured a contract valued at up to $15 million from Canada's Department of National Defence to purchase TPOXX®. The announcement describes the purchase as continuing Canada's commitment to smallpox preparedness for the Canadian Armed Forces.

Why it matters — The contract represents a potential sale of TPOXX to Canada's Department of National Defence, relevant to SIGA's commercial activity.

SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

SIGA Technologies held its Q2 2026 earnings call, with the transcript published by Seeking Alpha covering management's discussion of the company's quarterly results. The call addressed the company's financial and operational performance for the period.

Why it matters — SIGA watchers would care because the earnings call transcript provides direct insight into the company's latest quarterly performance and management's outlook.

Siga Technologies Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

SIGA Technologies reported second-quarter product-related revenue of $38 million, driven primarily by deliveries of intravenous TPOXX to the U.S. Strategic National Stockpile and oral TPOXX sales to international customers. The company noted the quarter reflected the variable timing of its government-focused procurement business after minimal product revenue in the first quarter.

Why it matters — A SIGA watcher would care because the quarter highlights the lumpy, government-driven nature of TPOXX revenue that underpins the company's financial performance.

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results

GlobeNewsWire · 30 July 2026neutral

SIGA Technologies announced it will host a webcast and conference call on August 6, 2026, to provide a business update following the release of its second-quarter 2026 financial results. The call will be led by CEO Diem Nguyen and CFO Daniel Luckshire.

Why it matters — Investors and analysts following SIGA will have an opportunity to hear management's perspective on the company's recent performance and strategic outlook during the earnings call.

Siga Technologies: Q2 Earnings Due, New TPOXX Orders A Must

Seeking Alpha · 28 July 2026negative

Seeking Alpha reports that SIGA remains a Hold with revenue visibility tied to BARDA contract renewal, while noting that TPOXX lost EU approval for MPOX and Q1 2026 results showed stagnant revenues and widening losses.

Why it matters — A SIGA watcher would care because TPOXX is the company's sole commercial product, and its revenue outlook depends heavily on government contract renewals amid shrinking market opportunities.

FAQ

Frequently asked questions about SIGA stock

How does Ticker Nerd's model rank SIGA?

As at 27 Oct 2026, SIGA Technologies, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

What is the SIGA stock forecast for 2030?

No analyst covering SIGA Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SIGA are extrapolating price history, which says nothing about the business.

How has SIGA stock performed over the past year?

SIGA Technologies, Inc. returned -56.3% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SIGA Technologies, Inc. do?

SIGA Technologies Inc. is a commercial-stage pharmaceutical company focused on health security and infectious disease countermeasures.

What is the latest news on SIGA?

The most recent item we track (GlobeNewsWire, 28 Oct 2026): "SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®". SIGA Technologies secured a contract valued at up to $15 million from Canada's Department of National Defence to purchase TPOXX®. The announcement describes the purchase as continuing Canada's commitment to smallpox preparedness for the Canadian Armed Forces.

Company

About SIGA Technologies, Inc.

SIGA Technologies Inc. is a commercial-stage pharmaceutical company focused on health security and infectious disease countermeasures. SIGA Technologies Inc. develops and commercializes antiviral medicines designed to address serious threats from orthopoxviruses and other emerging infectious diseases. Its lead product, TPOXX, is an oral antiviral treatment for smallpox, and the company also supplies an intravenous formulation for government use in public health preparedness settings. SIGA Technologies Inc. serves government customers and international markets through direct sales and distribution channels, making it a specialized participant in the biodefense and medical countermeasures segment of the pharmaceutical industry. Based in New York, SIGA Technologies Inc. concentrates on products that support outbreak response, national stockpiling, and treatment access for high-consequence viral diseases.

CEO Dr. Diem Nguyen M.B.A., Ph.D. · 49 employees · United States · https://www.siga.com